BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:brenetafusp readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of brenetafusp\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06112314-10943@assetmemo.bio
DTSTAMP:20261121T005809Z
DTSTART;VALUE=DATE:20271016
DTEND;VALUE=DATE:20271017
SUMMARY:brenetafusp: Phase 3 readout est. (NCT06112314)
DESCRIPTION:brenetafusp\, phase 3.\nStudy: IMC-F106C Regimen Versus Nivolum
 ab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)\nEst
 imated primary completion: 16 October 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/brenetafusp#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06112314
URL:https://assetmemo.bio/drug/brenetafusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686367-10943@assetmemo.bio
DTSTAMP:20261121T005809Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:brenetafusp: Phase 2 readout est. (NCT07686367)
DESCRIPTION:brenetafusp\, phase 2.\nStudy: Testing the Anti-Cancer Drug\, B
 renetafusp (IMCF106C)\, in Rare Cancers\nEstimated primary completion: 30 
 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/brenet
 afusp#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07686367
URL:https://assetmemo.bio/drug/brenetafusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
